These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16918890)

  • 21. The tolerance and efficacy of a postponed retreatment with infliximab in Crohn's disease primary responders.
    Laharie D; Chanteloup E; Chabrun E; Subtil C; Kowo M; El Hanafi K; DE Lédinghen V
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1240-8. PubMed ID: 19416134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidelines for treatment with infliximab for Crohn's disease.
    Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
    Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
    Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
    Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab treatment for symptomatic Crohn's disease strictures.
    Pelletier AL; Kalisazan B; Wienckiewicz J; Bouarioua N; Soulé JC
    Aliment Pharmacol Ther; 2009 Feb; 29(3):279-85. PubMed ID: 19035967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The incidence and management of infusion reactions to infliximab: a large center experience.
    Cheifetz A; Smedley M; Martin S; Reiter M; Leone G; Mayer L; Plevy S
    Am J Gastroenterol; 2003 Jun; 98(6):1315-24. PubMed ID: 12818276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of infusion reactions during infliximab treatment in patients with arthritis.
    Kapetanovic MC; Larsson L; Truedsson L; Sturfelt G; Saxne T; Geborek P
    Arthritis Res Ther; 2006; 8(4):R131. PubMed ID: 16869978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab dependency in children with Crohn's disease.
    Duricova D; Pedersen N; Lenicek M; Hradsky O; Bronsky J; Adamcova M; Elkjaer M; Andersen PS; Vitek L; Larsen K; Lukas M; Nevoral J; Wewer V; Munkholm P
    Aliment Pharmacol Ther; 2009 Apr; 29(7):792-9. PubMed ID: 19183163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab therapy in Crohn's disease: a pragmatic approach?
    Kevans D; Keegan D; Mulcahy HE; O'Donoghue DP
    Aliment Pharmacol Ther; 2006 Jul; 24(2):351-9. PubMed ID: 16842462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.
    Sands BE; Blank MA; Diamond RH; Barrett JP; Van Deventer SJ
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1127-36. PubMed ID: 16611273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infusion reactions and their management.
    Mayer L; Young Y
    Gastroenterol Clin North Am; 2006 Dec; 35(4):857-66. PubMed ID: 17129817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maintenance infliximab infusions forever?
    Lee SD; Surawicz CM
    Am J Gastroenterol; 2002 Nov; 97(11):2917-8. PubMed ID: 12425570
    [No Abstract]   [Full Text] [Related]  

  • 36. Rapid infliximab infusions in pediatric inflammatory bowel disease.
    Yeckes AR; Hoffenberg EJ
    J Pediatr Gastroenterol Nutr; 2009 Jul; 49(1):151-4. PubMed ID: 19516188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab.
    Moss AC; Treister NS; Marsee DK; Cheifetz AS
    Gastroenterology; 2007 Feb; 132(2):488, 829. PubMed ID: 17261307
    [No Abstract]   [Full Text] [Related]  

  • 38. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
    Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study.
    Breynaert C; Ferrante M; Fidder H; Van Steen K; Noman M; Ballet V; Vermeire S; Rutgeerts P; Van Assche G
    Am J Gastroenterol; 2011 Apr; 106(4):778-85. PubMed ID: 21407184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.